Blog
RSS FeedPosted by Michael Wonder on 19 Oct 2023
Ruxolitinib phosphate for the treatment of patients with polycythaemia vera
18 October 2023 - NICE has published final evidence based recommendations on the use of ruxolitinib phosphate (Jakavi) for the ...
Posted by Michael Wonder on 29 Nov 2022
Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 18 Nov 2019
NICE, in confidence: an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence
17 November 2019 - Health technology assessment aims to provide a transparent framework within which normative judgements can be applied for ...
Posted by Michael Wonder on 03 Jun 2018
Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund
1 June 2018 - Tesaro's ovarian cancer drug Zejula (niraparib), the first PARP inhibitor shown to be effective in patients ...
Posted by Michael Wonder on 20 Feb 2018
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000. ...
Posted by Michael Wonder on 27 Apr 2016
NICE & PBAC outcomes differ for new heart failure drug Entresto
27 April 2016 - Around 100,000 people in England and Wales could now benefit from treatment with Novartis’ revolutionary heart failure ...